Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management options in Behçet's disease.

J Andrews1, D O Haskard

  • 1Rheumatology Unit, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK.

Minerva Medica
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome.

Scientific reports·2016
Same author

The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-γ/CXCL10 IP-10 pathway.

Clinical and experimental immunology·2015
Same author

Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation.

Annals of the rheumatic diseases·2015
Same author

Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17.

Annals of the rheumatic diseases·2014
Same author

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.

Oncogene·2012
Same author

Persistence of TNFalpha in diabetic wounds.

Diabetologia·2010
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
Same journal

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026
See all related articles

Behçet's disease (BD) is a rare inflammatory disorder causing ulcers and inflammation in various organs. This review covers its clinical features and current management strategies for affected individuals.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Behçet's disease is a multi-system inflammatory disorder.
  • Characterized by recurrent oral/genital ulcers, eye inflammation, and skin lesions.
  • May involve locomotor, vascular, neurological, and gastrointestinal systems.

Purpose of the Study:

  • To review the clinical features of Behçet's disease.
  • To discuss current management options for the disorder.
  • To enhance understanding of this rare condition.

Main Methods:

  • Literature review of clinical features.
  • Synthesis of current management strategies.
  • Analysis of pathophysiology and epidemiology.

Related Experiment Videos

Main Results:

  • Behçet's disease presents with diverse clinical manifestations.
  • Pathophysiology may involve generalized vascular dysfunction.
  • The condition, though rare in Western Europe, has significant morbidity and mortality.

Conclusions:

  • Comprehensive review of Behçet's disease clinical spectrum.
  • Discussion of available therapeutic approaches.
  • Highlights the need for further research into pathophysiology and management.